Head-to-head evidence
apitegromab vs LAE102/LAE103
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Obesity
Shared mechanism: Activin/myostatin type II receptor · full Obesity pipeline
apitegromab
Developed by Scholar Rock
NCT06445075 · Phase 2 · completed
This was a randomized, double-blind, placebo-controlled trial in 102 adults with obesity taking tirzepatide, and apitegromab significantly reduced lean-mass loss compared with placebo (p=0.001). The primary measure was change in lean body mass, a body-composition measure, rather than the total weight loss that defines an obesity treatment's efficacy, so this is supportive evidence of a muscle-preserving effect rather than a direct efficacy readout for obesity.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
LAE102/LAE103
Developed by Laekna Limited
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: March 2028 · NCT07230496 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: apitegromab's landscape · LAE102/LAE103's landscape